Medicine
Drug-Induced QT Prolongation and Torsades de Pointes Risk Assessment
Quick fact
Over 100 common medications—including certain antibiotics, antidepressants, and antihistamines—can prolong the QT interval, and some can trigger torsades de pointes, a form of ventricular tachycardia that can degenerate into sudden cardiac death.
Why this is interesting
You've likely been on a medication that could quietly alter the electrical rhythm of your heart. How do we know which drugs pose a risk of a potentially fatal arrhythmia?
Read the full explanation
Understanding Drug-Induced QT Prolongation and Torsades de Pointes Risk Assessment
Think of your heart's beating as a finely tuned electrical cycle. The QT interval on an ECG represents the total time from the start of ventricular electrical activation (depolarization) to its completion (repolarization). Repolarization is the 'reset' phase essential for the next beat. Many drugs, through various mechanisms, can slow this reset process, stretching out the QT interval. This is not inherently harmful, but when the QT is excessively prolonged, it creates an environment where the heart rhythm can become unstable and a particular dangerous arrhythmia, torsades de pointes, may emerge. While any drug that blocks the hERG potassium channel can delay repolarization, the likelihood that it causes TdP depends on many factors, including the degree of QT prolongation and the patient's baseline risk.
A deeper explanation
The primary cellular mechanism is inhibition of the hERG potassium channel, which carries the rapidly activating delayed rectifier potassium current (IKr) crucial for terminating the action potential plateau and initiating repolarization. When a drug binds to the hERG channel, it partially blocks the outward potassium current, prolonging the action potential duration and thus the QT interval on the surface ECG. This prolongation is not uniform across the myocardium, creating heterogeneity in repolarization. This dispersion sets the stage for early afterdepolarizations (EADs)—abnormal depolarizations that occur before repolarization is complete. If an EAD reaches sufficient amplitude, it can trigger a premature beat; if it occurs in the context of regional repolarization differences, a reentrant circuit can be established, precipitating torsades de pointes. Risk assessment for a given drug integrates multiple dimensions: the magnitude of QT prolongation (typically corrected for heart rate, QTc), the affinity for hERG, the drug's concentration and route of administration, and patient-specific factors such as baseline QT, electrolyte levels (e.g., hypokalemia), age, sex, and concomitant use of other QT-prolonging agents. Regulatory bodies like the FDA require thorough QT studies during drug development to evaluate the drug's effect on the QTc interval and, if significant, the drug may be restricted or contraindicated in patients with risk factors.